PharmExec

MARCH 14, 2024

Ian Baer, Founder and Chief Soothsayer, Sooth, discusses how pharmaceutical companies and healthcare advertising agencies can adapt their strategies to attract Gen-Z.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

Pharmacy Times

MARCH 14, 2024

This finding was evident in both examined groups and regardless of the patients' B-cell maturation antigen-directed therapy status.

160

160

STAT

MARCH 14, 2024

A new study suggests the antiviral drug obeldesivir may be effective in curing Ebola Sudan infections, for which there are currently no approved vaccines or treatments. Scientists at the University of Texas Medical Branch in Galveston tested the drug, made by Gilead, in primates, starting treatment 24 hours after the animals were given what should have been a lethal dose of Sudan ebolavirus by intramuscular injection.

Vaccines 145

Vaccines 145

Pharmacy Times

MARCH 14, 2024

At 4 months, 75% of participants achieved remission and no longer showed signs of depression symptoms in a phase 2 clinical trial.

FDA 149

FDA 149

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

STAT

MARCH 14, 2024

WASHINGTON — Novo Nordisk’s newly won permission to market the heart benefits of its obesity drug Wegovy could provide a backdoor way to expand access to the drug for people on Medicare, experts told STAT. Currently, Medicare is prohibited by law from covering medications for obesity treatment alone. While companies that manufacture wildly popular anti-obesity medications and their allies haven’t been successful in lobbying Congress to change the law , the Food and Drug

Labelling 145

Labelling Insurance 145

Drug Topics

MARCH 14, 2024

The approval, awarded to Madrigal Pharmaceuticals, was based on phase 3 data demonstrating that resmetirom achieved broad treatment effects in patients with MASH with liver fibrosis.

FDA 138

FDA 138

Fierce Healthcare

MARCH 14, 2024

Mayo Clinic wants to help digital health more quickly—and more cost-effectively—bring its innovations into the hospital. | The Mayo Clinic Platform's Solutions Studio program will work with digital health companies "from idea to integration into clinical workflows." The system pitches it as a cost-effective way for innovators to bring their offerings to the point of care.

Mayo Clinic 134

Mayo Clinic Hospitals 134

STAT

MARCH 14, 2024

LONDON — The U.K.’s cost-effectiveness watchdog said Thursday it is not yet recommending Vertex’s CRISPR-based therapy for sickle cell disease, saying in draft guidance it has questions about the medicine’s lasting benefits for patients. U.K. regulators approved the therapy , known as Casgevy or exa-cel, last year, granting it the world’s first authorization for any CRISPR-based medicine.

138

138

Pharmacy Times

MARCH 14, 2024

The drug is indicated for patients 5 years of age and older with progressive familial intrahepatic cholestasis and cholestatic pruritus in pediatric patients with Alagille syndrome.

FDA 132

FDA 132

STAT

MARCH 14, 2024

Have you heard the news? I’m launching a weekly email newsletter starting on March 28. It’s called Adam’s Biotech Scorecard and it’s exclusively for STAT subscribers. One catch: We need you to sign up, which you can do here. What should you expect to see in my newsletter each week? Unfiltered, uncompromising, and (hopefully) valuable insight and analysis from the intersection of Wall Street and biotech.

134

134

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmacy Times

MARCH 14, 2024

The tool consolidates and highlights key features that would be considered when choosing a biosimilar adalimumab.

132

132

STAT

MARCH 14, 2024

LONDON —   AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial. The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met.   AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline.

132

132

Pharmaceutical Technology

MARCH 14, 2024

The funds will be used to expand Zephyr AI's headcount and enhance datasets.

124

124

STAT

MARCH 14, 2024

What happens when an approved drug doesn’t work? Why don’t patients want gene therapy? And is MASH still a big deal? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Bioethicist Holly Fernandez Lynch joins us to discuss the case of Amylyx Pharmaceuticals’ treatment for ALS and what its failure means for drug development.

125

125

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Fierce Healthcare

MARCH 14, 2024

Providers are still feeling the pain brought on by the cyberattack on Change Healthcare, and they're continuing to push insurers and the feds to beef up their responses. | Providers are still feeling the pain brought on by the cyberattack on Change Healthcare, and they're continuing to push insurers and the feds to beef up their responses.

Insurance 124

Insurance 124

Pharmacy Times

MARCH 14, 2024

Results from the phase 3 RATIONALE 302 trial showed tislelizumab-jsgr prolonged survival compared to chemotherapy in patients who received prior systemic treatment.

Chemotherapy 123

Chemotherapy FDA 123

Fierce Healthcare

MARCH 14, 2024

Salesforce launched a new healthcare AI assistant within its customer relationship management system, marking the latest tech company trying to expand its reach in the healthcare market. | Salesforce launched a new healthcare AI assistant within its customer relationship management system, marking the latest tech company trying to expand its reach in the healthcare market.

124

124

Drug Topics

MARCH 14, 2024

With growing concerns around opioid use disorder, interventional pain management for patients with cancer can provide effective relief without the side effects associated with medication.

123

123

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Fierce Healthcare

MARCH 14, 2024

Despite challenges with compensation, staffing shortages, safety and more, most nurses want to remain in the field until retirement, a new report found. | The report, which also covered nurses' thoughts on healthcare AI, included Incredible Health’s proprietary data from the 1 million nurses using its platform and the findings of a survey that reached more than 3,300 nurses working in the hospital setting.

Hospitals 122

Hospitals 122

Pharmacy Times

MARCH 14, 2024

Raj Gupta, DC, discusses holistic approaches to managing type 2 diabetes without medication by addressing root causes like diet, toxins, and stress.

121

121

STAT

MARCH 14, 2024

Rise and shine, everyone, another busy day is on the way. We can tell because the official mascots are especially enjoying the Pharmalot grounds now that spring is springing and various work crews are dotting the nearby environs. This is an especially busy day for us, in fact, since we are hosting a session later on biosimilars — mark your calendar for 1 p.m.

121

121

Fierce Pharma

MARCH 14, 2024

Twenty months after the FDA’s original target decision date on cancer drug tislelizumab, BeiGene has finally received the U.S. go-ahead. | Twenty months after the FDA's original target decision date, BeiGene has finally received the U.S. go-ahead for its PD-1 inhibitor Tevimbra.

FDA 120

FDA 120

STAT

MARCH 14, 2024

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Hello, everyone. Damian here with a reminder that my colleague Ed Silverman is hosting a discussion today about the long-awaited arrival of Humira biosimilars and all they portend for drug costs, insurance coverage, and pharma revenues.

Insurance Coverage 120

Insurance Coverage Insurance 120

Pharmacy Times

MARCH 14, 2024

The findings suggest that ruxolitinib cream could aid itch, pain, and sleep disturbance.

120

120

Fierce Pharma

MARCH 14, 2024

Just as BeiGene’s Brukinsa encroaches on C | Just as BeiGene’s Brukinsa encroaches on CAR-T territory, Bristol Myers Squibb has brought its CAR-T therapy Breyanzi into chronic lymphocytic leukemia, which is considered the BTK inhibitor class’s home turf.

FDA 119

FDA 119

Pharmacy Times

MARCH 14, 2024

Antimicrobial stewardship is crucial for all health care professionals—not just those in a hospital setting

Hospitals 117

Hospitals 117

pharmaphorum

MARCH 14, 2024

AstraZeneca adds a late-stage rare disease therapy to its pipeline, buying Amolyt Pharma and hypoparathyroidism drug eneboparatide for $800 million upfront.

115

115

Fierce Pharma

MARCH 14, 2024

Ever since Vertex and CRISPR therapeutics scored a groundbreaking U.K. | In its draft guidance, the U.K.'s cost effectiveness watchdog recognized the need for the sickle cell therapy but needs more data from Vertex on its effectiveness in an updated managed access proposal.

115

115

pharmaphorum

MARCH 14, 2024

Cybin files a $150m placement on the back of new clinical data with its psychedelic drug CYB003 for depression and an FDA breakthrough designation.

FDA 115

FDA 115

STAT

MARCH 14, 2024

Editor’s note: A livestream of this event will be embedded below at 1 p.m. ET. Several biosimilar versions of Humira, which for years has been the world’s best-selling medicine, entered the U.S. market over the past year. What has that meant for insurance coverage and the way drugmakers are marketing these medicines? Join leading experts to discuss the impact on the industry and patients.

Insurance Coverage 108

Insurance Coverage Insurance 108

pharmaphorum

MARCH 14, 2024

Researchers have developed an artificial intelligence algorithm to assist in the diagnosis of lymph node cancer from medical images that has an accuracy of around 90%. The team carried out a retrospective study on the deep learning model, using PET-CT scans from more than 5,000 patients treated for lymphoma at Memorial Sloan Kettering Cancer Centre in the US and the Medical University of Vienna in Austria.

111

111

Fierce Pharma

MARCH 14, 2024

After charting multiple personalized medicine expansions in recent years, contract manufacturer Charles River Laboratories is back with another gene therapy pact—this time centered on an adeno-asso | After charting multiple personalized medicine expansions in recent years, contract manufacturer Charles River Laboratories is back with another gene therapy pact—this time centered on an adeno-associated virus 9 (AAV9) candidate meant to serve as a non-opioid alternative for rare disease patients li

105

105

pharmaphorum

MARCH 14, 2024

Munich-based antibody-drug conjugate (ADC) specialist Tubulis has completed a sizeable Series B2 financing that shows sustained investor appetite for the ADC category, particularly for companies with technologies that can enhance the safety of these drugs.

105

105